Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -4 of 4
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
11/11/2008
 
First Published:
8/1/1997
1.
Phase III Study of Early High-Dose Chemoradiotherapy and Autologous Peripheral Blood Stem Cell Transplantation Versus Conventional Dose Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Patients with Intermediate- or High-Grade Non-Hodgkin's Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
15 to 65
NCI
SWOG-S9704
CAN-NCIC-LY11, CALGB-59903, ECOG-S9704, S9704, NCT00004031, LY11
Last Modified:
2/9/2008
 
First Published:
11/24/2002
2.
Phase III Randomized Study of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With Versus Without Rituximab in Elderly Patients With Aggressive Non-Hodgkin's Lymphoma (Randomized portion of the study completed as of 6/2005)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
61 to 80
Other
DSHNHL-1999-1A
EU-20243, NCT00052936
Last Modified:
1/10/2009
 
First Published:
9/24/2003
3.
Phase II Study of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone and Radiotherapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Patients With Aggressive High-Risk Stage I or IE or Non-Bulky Stage II or IIE CD20-Positive Non-Hodgkin's Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
Over 18
NCI
SWOG-S0313
S0313, NCT00070018
Last Modified:
1/5/2009
 
First Published:
3/24/2005
4.
Treatment of Children with Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin's Disease
Phase
Type
Status
Age
Sponsor
Protocol IDs
No phase specified
Treatment
Active
21 and under
NCI
COG-AHOD03P1
AHOD03P1, NCT00107198
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute